Targeted therapies for advanced bladder cancer: new strategies with FGFR inhibitors.

Casadei, Chiara; Dizman, Nazli; Schepisi, Giuseppe; Cursano, Maria Concetta; Basso, Umberto; Santini, Daniele; Pal, Sumanta K; De Giorgi, Ugo

Casadei, Chiara; Dizman, Nazli; Schepisi, Giuseppe; Cursano, Maria Concetta; Basso, Umberto; Santini, Daniele; Pal, Sumanta K; De Giorgi, Ugo.

Afiliación

Casadei C; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Dizman N; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
Schepisi G; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Cursano MC; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.
Basso U; Medical Oncology Unit, Istituto Oncologico Veneto, IOV-IRCCS, Padova, Italy.
Santini D; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome, Italy.
Pal SK; Department of Medical Oncology and Therapeutics Research, City of Hope Comprehensive Cancer Center, Duarte, CA, USA.
De Giorgi U; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Via Maroncelli 40, Meldola, 47014, Italy.

Ther Adv Med Oncol ; 11: 1758835919890285, 2019.

Article en En | MEDLINE | ID: mdl-31803255

Palabras clave

FGFR inhibitors; erdafitinib; infigratinib; rogaratinib; urothelial cancer; vofatamab

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Idioma: En Revista: Ther Adv Med Oncol Año: 2019 Tipo del documento: Article País de afiliación: Italia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google